Nursing Elites

1. A client with a history of migraine headaches is starting prophylaxis therapy with Propranolol. Which of the following findings in the client history should be reported to the provider by the nurse?

• A. The client had a prior myocardial infarction.
• B. The client takes warfarin for atrial fibrillation.
• C. The client takes an SSRI for depression.
• D. An ECG indicates a first-degree heart block.

Correct answer: D

Rationale: Propranolol is contraindicated in clients with a first-degree heart block due to its negative chronotropic properties that can further slow the heart rate. This can worsen conduction through the atrioventricular node, potentially leading to heart block progression. Therefore, the nurse should report the finding of a first-degree heart block to the provider before initiating Propranolol therapy. Choices A, B, and C are not contraindications for Propranolol therapy. A prior myocardial infarction, taking warfarin for atrial fibrillation, or using an SSRI for depression do not directly impact the initiation of Propranolol therapy in a client with a history of migraine headaches.

2. A client is prescribed Amlodipine. Which of the following adverse effects should the nurse monitor?

• A. Tachycardia
• B. Peripheral edema
• C. Hyperglycemia
• D. Hypertension

Correct answer: B

Rationale: Corrected Rationale: Amlodipine, a calcium channel blocker, can lead to peripheral edema as an adverse effect. The nurse should assess the client for swelling in the lower extremities, a common manifestation of this side effect. Monitoring for peripheral edema is crucial to ensure early detection and appropriate management. Tachycardia (Choice A) is not a common adverse effect of Amlodipine. Hyperglycemia (Choice C) is not typically associated with Amlodipine use. Hypertension (Choice D) is the condition for which Amlodipine is prescribed to treat, not an adverse effect of the medication.

3. A healthcare professional is reviewing a new prescription for Ondansetron 4 mg PO PRN for nausea and vomiting for a client who has Hyperemesis Gravidarum. The healthcare professional should clarify which of the following parts of the prescription with the provider?

• A. Name
• B. Dosage
• C. Route
• D. Frequency

Correct answer: D

Rationale: The prescription provided includes the medication name, dosage, and route of administration. However, it lacks information about the frequency or timing of the medication administration. In this case, it is crucial to clarify the frequency with the provider to ensure the safe and effective use of the medication for the client with Hyperemesis Gravidarum.

4. A healthcare professional is reviewing the medical record of a client with a new prescription for Epoetin Alfa. Which of the following findings should the professional report to the provider?

• A. The client has a history of hypertension.
• B. The client has a hemoglobin level of 10 g/dL.
• C. The client has a history of chronic kidney disease.
• D. The client has a blood pressure of 140/90 mm Hg.

Correct answer: C

Rationale: The correct answer is C. Chronic kidney disease is a contraindication for the use of Epoetin Alfa because it can worsen hypertension, increase the risk of cardiovascular events, and lead to adverse outcomes. Epoetin Alfa is used to treat anemia by stimulating red blood cell production, but in the presence of chronic kidney disease, it can exacerbate hypertension and contribute to cardiovascular complications. Choices A, B, and D are not directly related to the contraindication of Epoetin Alfa in the presence of chronic kidney disease.

5. What is the antidote for copper toxicity?

• A. Glucagon
• B. Aminocaproic acid
• C. Atropine
• D. Penicillamine

Correct answer: D

Rationale: Penicillamine is the specific chelating agent used for copper toxicity. It forms stable complexes with copper, which are then excreted in the urine. Glucagon is used for treating hypoglycemia, aminocaproic acid is used to treat bleeding disorders, and atropine is used as an antidote for certain types of poisoning, such as organophosphate toxicity.

Similar Questions